The recent surge in funding into specialized pharmaceutical companies, particularly those focusing on novel therapies and challenging drug development programs, has fueled what some are calling "High Investor Pharma." While the possibility for revolutionary treatments and substantial returns is certain, the connected risks are also considerable. Ma